Ziccum AB (publ) (ZICC.ST)
SEK 0.35
(-9.07%)
SEK 0.35
(-9.07%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | -4.18 Million SEK | -186.13% |
| 2022 | -1.46 Million SEK | 0.0% |
| 2021 | - SEK | 0.0% |
| 2020 | - SEK | 0.0% |
| 2019 | - SEK | 100.0% |
| 2018 | -690 Thousand SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | -3.76 Million SEK | 10.12% |
| 2024 Q3 | -1.54 Million SEK | 100.0% |
| 2024 Q2 | -4.18 Million SEK | -11.05% |
| 2023 FY | -4.18 Million SEK | -186.13% |
| 2023 Q1 | -1.32 Million SEK | 9.56% |
| 2023 Q3 | -3.87 Million SEK | -123.96% |
| 2023 Q2 | -1.73 Million SEK | -30.82% |
| 2023 Q4 | -4.18 Million SEK | -7.99% |
| 2022 Q4 | -1.46 Million SEK | 17.19% |
| 2022 Q2 | -2.17 Million SEK | 1.4% |
| 2022 FY | -1.46 Million SEK | 0.0% |
| 2022 Q1 | -2.2 Million SEK | -110.89% |
| 2022 Q3 | -1.76 Million SEK | 18.79% |
| 2021 Q2 | -1.16 Million SEK | 0.0% |
| 2021 FY | - SEK | 0.0% |
| 2021 Q3 | -1.35 Million SEK | -15.98% |
| 2021 Q1 | - SEK | 0.0% |
| 2021 Q4 | -1.04 Million SEK | 22.44% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 FY | - SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 FY | - SEK | 100.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2018 FY | -690 Thousand SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 2.00 SEK | 209450100.0% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| BioArctic AB (publ) | - SEK | Infinity% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 41.298% |
| Mendus AB (publ) | - SEK | Infinity% |
| Genovis AB (publ.) | 14.9 Million SEK | 128.105% |
| Intervacc AB (publ) | 10.48 Million SEK | 139.96% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | Infinity% |
| Active Biotech AB (publ) | -2500.00 SEK | -167460.0% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 111.891% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | 146.195% |
| Aptahem AB (publ) | - SEK | Infinity% |
| Vicore Pharma Holding AB (publ) | - SEK | Infinity% |
| Kancera AB (publ) | -1950.00 SEK | -214720.513% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | 232.984% |
| Saniona AB (publ) | 1.00 SEK | 418900100.0% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | -157.626% |
| Biovica International AB (publ) | 2.19 Million SEK | 290.496% |
| Spago Nanomedical AB (publ) | 1.00 SEK | 418900100.0% |
| AcouSort AB (publ) | 2.08 Million SEK | 301.394% |
| Xintela AB (publ) | 398 Thousand SEK | 1152.513% |
| Abliva AB (publ) | - SEK | Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | 698.429% |
| Karolinska Development AB (publ) | - SEK | Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | -385.4% |
| Amniotics AB (publ) | 534 Thousand SEK | 884.457% |
| 2cureX AB (publ) | -1000.00 SEK | -418800.0% |
| CombiGene AB (publ) | -1.79 Million SEK | -132.852% |
| Asarina Pharma AB (publ) | - SEK | Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 120.506% |
| Camurus AB (publ) | 100.95 Million SEK | 104.149% |
| Corline Biomedical AB | -3.85 Million SEK | -8.608% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | 419000.0% |
| Isofol Medical AB (publ) | - SEK | Infinity% |
| I-Tech AB | 4.28 Million SEK | 197.874% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | 142.78% |
| Cyxone AB (publ) | - SEK | Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | Infinity% |
| Biosergen AB | -4.92 Million SEK | 15.013% |
| Cantargia AB (publ) | - SEK | Infinity% |
| NextCell Pharma AB | 545.23 Thousand SEK | 868.29% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 109.568% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | -837.166% |
| Nanologica AB (publ) | 2.97 Million SEK | 240.901% |
| SynAct Pharma AB | - SEK | Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | Infinity% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | -1204.395% |
| LIDDS AB (publ) | - SEK | Infinity% |
| Lipum AB (publ) | - SEK | Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 135.368% |
| Alzinova AB (publ) | -3.27 Million SEK | -27.791% |
| Oncopeptides AB (publ) | 2.42 Million SEK | 272.742% |
| Pila Pharma AB (publ) | 1.00 SEK | 418900100.0% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | -281797.712% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | 203.842% |
| Simris Alg AB (publ) | 1.09 Million SEK | 483.96% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 117.418% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 103.92% |
| Ascelia Pharma AB (publ) | - SEK | Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | 507.49% |